<DOC>
	<DOCNO>NCT01932489</DOCNO>
	<brief_summary>Prior use genomic test patient inclusion clinical trial , essential Jules Bordet Institute ( JBI ) pilot logistical technical aspect examine feasibility turnaround time perform obtain data key molecular assay . Patients metastatic colorectal cancer , non-small cell lung cancer melanoma enrol . Biopsie metastatic lesion perform . A targeted cancer gene screen assay perform use DNA sequence . Results discuss molecular screen tumor board .</brief_summary>
	<brief_title>The Jules Bordet Institute Molecular Profiling Program Feasibility Trial</brief_title>
	<detailed_description />
	<mesh_term>Carcinoma , Non-Small-Cell Lung</mesh_term>
	<mesh_term>Colorectal Neoplasms</mesh_term>
	<criteria>Written inform consent study procedure accord local regulatory requirement prior enrollment study . Age â‰¥ 18 year . Histologically proven metastatic locally recurrent CRC , NSCLC melanoma . Tumor tissue ( FFPE frozen ) recurrent metastatic lesion available research purpose . Eastern Cooperative Oncology Group ( ECOG ) Performance Status &gt; 2 . The biopsy procedure estimate risky patient . Any antiVEGF antiVEGFR treatment administer less 3 week new biopsy procedure . No appropriate washout period patient anticoagulation therapy .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>October 2014</verification_date>
</DOC>